Shield STX.L Revenue Grew 157% But Shares Just Fell
STX surges 157% in revenue: Shield Therapeutics stock analysis — valuation, buy or sell 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Shield Therapeutics plc (STX) and its flagship oral iron therapy ACCRUFeR, which is spearheading a massive commercial turnaround in the U.S. and entering adjacent global markets. With total Group revenue growing 54.4% YoY in FY25 and Q1 2026 operating profits turning positive, the key…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.